Scholar Rock Holding (SRRK) Capital Expenditures Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -74.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.91% |
| Dec 31, 2025 | 45.45% |
| Sep 30, 2025 | 170.97% |
| Jun 30, 2025 | 571.88% |
| Mar 31, 2025 | 1,984.62% |
| Jun 30, 2024 | -21.95% |
| Mar 31, 2024 | -56.67% |
| Jun 30, 2023 | -91.91% |
| Mar 31, 2023 | -92.74% |
| Dec 31, 2022 | 75.65% |
| Sep 30, 2022 | -119.85% |
| Jun 30, 2022 | 130.23% |
| Mar 31, 2022 | -82.14% |
| Dec 31, 2021 | -72.54% |
| Sep 30, 2021 | 122.34% |
| Jun 30, 2021 | -714.29% |
| Mar 31, 2021 | 23,020.00% |
| Dec 31, 2020 | 34.29% |
| Sep 30, 2020 | 13.16% |
| Jun 30, 2020 | 159.87% |
| Mar 31, 2020 | -97.93% |
| Dec 31, 2019 | 109.70% |
| Sep 30, 2019 | 170.12% |
| Jun 30, 2019 | -354.75% |
| Mar 31, 2019 | 3,615.38% |
| Dec 31, 2018 | 132.12% |
| Sep 30, 2018 | 499.33% |